[2] Since 2019, she is the medical director of the university hospital department Innovation en santé Mentale, Psychiatrie et AddiCTologie du Grand-Paris-Sud (DMU IMPACT)[3] within Centre hospitalier universitaire Henri-Mondor (AP-HP) and of the Fédération hospitalo-universitaire de médecine de précision en psychiatrie et addictologie (FHU ADAPT) since 2020.
Since 2007, and in addition to her responsibilities as a university professor and hospital practitioner, Prof. Leboyer has directed the FondaMental foundation,[8] a French foundation for scientific cooperation in mental health, created in July 2007 by the ministries in charge of research and health, following a call for tenders from the RTRS (Réseau Thématique de Recherche et de Soins),[9] with the objective of innovation in the organization of care, support for research, training and information on mental illness.
[11][12] This award pays tribute to a French scientific researcher whose work has led to remarkable progress in the knowledge of human physiology, in therapeutics, and more broadly, in the field of health.
Thus, a program like PEPR PROXY, chosen under France 2030, is not only competitive but also a mark of distinction, reflecting the project's potential to set new standards and advance the field of psychiatry on a global scale.
[44] She also participated in the description of connectivity anomalies associated with the most severe psychiatric pathologies[45] or the increase of dendritic density in bipolar patients taking lithium.
[59] In this respect, she has contributed to the creation of several national networks of expert centers, specialized multidisciplinary structures, care and research platforms in the field of bipolar disorders,[60] schizophrenia,[61] resistant depression, and high functioning autism.
This position seems to diverge from the movement to recognize Autism Spectrum Disorders as a set of disabilities (and not as a pathology), as defined in particular by the French Law for equal rights and opportunities, participation and citizenship of disabled people (February 11, 2005), commented on by the association Autisme France in a document[64] from February 2015 highlighting the current difficulty for MDPHs to recognize autism other than as a psychological disorder, due to the "omnipotence" of doctors in multidisciplinary team meetings, as well as the pressures encountered by parents of autistic children who are pushed to seek "care" for their child before sending him or her to school.
[65] According to the journalist Olivia Cattan, Marion Leboyer had knowledge of wild therapeutic trials conducted by doctors of the Chronimed group on autistic children.
In 2017, at the request of the Fondation Autisme[69] (Bertrand Jacques and Florent Chapel), Prof. Leboyer had considered setting up an AntibiAutism project "Minocycline treatment of High Functioning Autism Spectrum Disorder symptoms in adult patients: a double-blinded randomized controlled study", which was retained by the French Ministry of Health's Direction générale de l'Offre de soins (DGOS) within the framework of the national clinical research hospital program (PHRC-N).
[70] This project, which aimed to test the efficacy of an antibacterial antibiotic (Minocycline) in adults diagnosed with autism spectrum disorder without intellectual delay, was abandoned on the initiative of Prof. Leboyer, before any trial on patients, so that it does not appear on the 2017 PHRC-N list.